These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://craigvakp585359.mpeblog.com/69786763/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide